Seattle Genetics, Inc., a biotechnology company, engages in the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. Its products are based on two technologies, genetically engineered monoclonal antibodies and monoclonal antibody-drug conjugates, which develop monoclonal antibodies that kill target cells and raise the potency of monoclonal antibodies by linking them to a cell killing payload. The company’s product candidates include SGN-30, a monoclonal antibody targeting the CD30 antigen, which is in phase II clinical trials for treatment of systemic anaplastic large cell lymphoma (ALCL), cutaneous ALCL, and Hodgkin’s...